Nisa Investment Advisors LLC Has $175,000 Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Nisa Investment Advisors LLC decreased its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 7.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,893 shares of the biotechnology company’s stock after selling 148 shares during the period. Nisa Investment Advisors LLC’s holdings in Blueprint Medicines were worth $175,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in BPMC. Price T Rowe Associates Inc. MD raised its holdings in shares of Blueprint Medicines by 15.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,250,823 shares of the biotechnology company’s stock worth $592,954,000 after acquiring an additional 821,868 shares during the last quarter. Millennium Management LLC increased its holdings in Blueprint Medicines by 540.0% during the 2nd quarter. Millennium Management LLC now owns 627,626 shares of the biotechnology company’s stock worth $67,646,000 after purchasing an additional 529,566 shares in the last quarter. 1832 Asset Management L.P. raised its stake in shares of Blueprint Medicines by 200,159.4% in the second quarter. 1832 Asset Management L.P. now owns 502,651 shares of the biotechnology company’s stock worth $54,176,000 after purchasing an additional 502,400 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of Blueprint Medicines by 79.3% in the second quarter. Point72 Asset Management L.P. now owns 501,581 shares of the biotechnology company’s stock valued at $54,060,000 after purchasing an additional 221,813 shares in the last quarter. Finally, Clearbridge Investments LLC purchased a new position in shares of Blueprint Medicines during the second quarter valued at approximately $23,817,000.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Morgan Stanley raised their price objective on Blueprint Medicines from $110.00 to $115.00 and gave the company an “equal weight” rating in a research note on Friday, July 12th. Guggenheim boosted their price target on shares of Blueprint Medicines from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Robert W. Baird increased their price objective on shares of Blueprint Medicines from $112.00 to $127.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. UBS Group began coverage on Blueprint Medicines in a research note on Thursday, October 24th. They issued a “neutral” rating and a $88.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a report on Thursday, October 31st. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $120.39.

Blueprint Medicines Stock Performance

NASDAQ BPMC opened at $99.63 on Thursday. The firm has a market cap of $6.33 billion, a P/E ratio of -47.55 and a beta of 0.59. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The company’s 50 day moving average is $88.81 and its 200-day moving average is $98.65. Blueprint Medicines Co. has a 12-month low of $56.74 and a 12-month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business had revenue of $128.20 million for the quarter, compared to analysts’ expectations of $127.56 million. During the same quarter in the previous year, the firm posted ($2.20) EPS. The business’s revenue for the quarter was up 126.5% compared to the same quarter last year. Sell-side analysts predict that Blueprint Medicines Co. will post -3.65 earnings per share for the current year.

Insider Buying and Selling

In other Blueprint Medicines news, insider Fouad Namouni sold 3,633 shares of Blueprint Medicines stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total transaction of $324,499.56. Following the completion of the transaction, the insider now owns 69,070 shares of the company’s stock, valued at $6,169,332.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.21% of the stock is currently owned by insiders.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.